Subheading · Chapter 30 · Heading 3004
3004.90: Medicaments: other
Other medicines, dosed or for retail sale
Official description Other
3004.90 is the HS subheading for other medicines, dosed or for retail sale, under heading 3004 in chapter 30.
What you pay
Importing into UK
Rates by national line · UK Global Tariff
UK lines →- 3004 90 00 00 Other Free
Additional duties and import rules
Charges on top of the customs duty, and rules the goods must meet at the border.
Additional duties and charges 1
- Additional dutyAdditional duties 35%
- Applies to goods from
- Belarus, Russia
- Legal act
- 2022 No. 598
- Documents
- 9014
Import requirements 5
- Import controlHome Office Controlled Drugs (import)
- Applies to goods from
- all countries
- Legal act
- 2001 No. 3998
- Documents
- 9113
- 913Y
- Import controlRestriction on entry into free circulation
- Applies to goods from
- all countries
- Legal act
- S.I. 2020/1354, S.I. 2022/395
- Documents
- 9229
- 9009
- 9010
- 9017
- Import controlRestriction on entry into free circulation
- Applies to goods from
- all countries
- Legal act
- S.I. 2019/583
- Documents
- L100 Import licence "controlled substances" (ozone), issued by the Commission
- Y902
- 9Y06
- Import controlImport control - CITES
- Applies to goods from
- all countries
- Legal act
- 2021 No. 54
- Import controlImport control on seal products
- Applies to goods from
- all countries
- Legal act
- 2018 No. 1034
- Documents
- C679 Attesting Document (seal product), issued by a recognised body in accordance with Regulation (EU) No 737/2010 prior to 18 October 2015
- C680 Written notification of import and document giving evidence where the products were acquired (seal product)
- C683 European Union - Attesting document for seal products resulting from hunt by Inuit or other indigenous communities for placing on the Union's market in accordance with Article 3 (1) of Regulation (EC) No 1007/2009 on trade in seal products
- Y032 Other goods than those seal products mentioned in Regulation (EU) 2015/1850 (OJ L 271)
Preferential rates by country
| Agreement or scheme | Countries | Rate |
|---|---|---|
| standard rate (no agreement) | — | Free |
| DCTS Comprehensive | Afghanistan, Angola, Bangladesh, Benin and 38 moreAfghanistan, Angola, Bangladesh, Benin, Bhutan, Burkina Faso, Burundi, Cambodia, Central African Republic, Chad, Comoros, Congo - Kinshasa, Djibouti, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Kiribati, Laos, Liberia, Malawi, Mali, Mauritania, Myanmar (Burma), Nepal, Niger, Rwanda, São Tomé & Príncipe, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Tanzania, Timor-Leste, Togo, Tuvalu, Uganda, Yemen, Zambia | Free |
| European Union (including code "EU") | Free | |
| CARIFORUM | Antigua & Barbuda, Bahamas, Barbados, Belize and 10 moreAntigua & Barbuda, Bahamas, Barbados, Belize, Dominica, Dominican Republic, Grenada, Guyana, Jamaica, St Kitts & Nevis, St Lucia, St Vincent & the Grenadines, Suriname, Trinidad & Tobago | Free |
| OCTs (Overseas Countries and Territories) | Anguilla, Bermuda, British Indian Ocean Territory, British Virgin Islands and 7 moreAnguilla, Bermuda, British Indian Ocean Territory, British Virgin Islands, Cayman Islands, Falkland Islands, Montserrat, Pitcairn Islands, South Georgia & South Sandwich Islands, St Helena, Turks & Caicos Islands | Free |
| Central America | Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama | Free |
| SADC EPA | Botswana, Eswatini, Lesotho, Mozambique, Namibia | Free |
| Eastern and Southern Africa States | Madagascar, Mauritius, Seychelles, Zimbabwe | Free |
| CPTPP | Brunei, Malaysia | Free |
| UK–Andorra agreement | Andorra | Free |
| UK–Albania agreement | Albania | Free |
| UK–Australia agreement | Australia | Free |
| UK–Canada agreement | Canada | Free |
| UK–Switzerland agreement | Switzerland | Free |
| UK–Côte d’Ivoire agreement | Côte d’Ivoire | Free |
| UK–Chile agreement | Chile | Free |
| UK–Cameroon agreement | Cameroon | Free |
| UK–Colombia agreement | Colombia | Free |
| UK–Ceuta & Melilla agreement | Ceuta & Melilla | Free |
| UK–Ecuador agreement | Ecuador | Free |
| UK–Egypt agreement | Egypt | Free |
| UK–Fiji agreement | Fiji | Free |
| UK–Faroe Islands agreement | Faroe Islands | Free |
| UK–Georgia agreement | Georgia | Free |
| UK–Ghana agreement | Ghana | Free |
| UK–Israel agreement | Israel | Free |
| UK–India agreement | India | Free |
| UK–Iceland agreement | Iceland | Free |
| UK–Jordan agreement | Jordan | Free |
| UK–Japan agreement | Japan | Free |
| UK–Kenya agreement | Kenya | Free |
| UK–South Korea agreement | South Korea | Free |
| UK–Lebanon agreement | Lebanon | Free |
| UK–Liechtenstein agreement | Liechtenstein | Free |
| UK–Morocco agreement | Morocco | Free |
| UK–Moldova agreement | Moldova | Free |
| UK–North Macedonia agreement | North Macedonia | Free |
| UK–Mexico agreement | Mexico | Free |
| UK–Norway agreement | Norway | Free |
| UK–New Zealand agreement | New Zealand | Free |
| UK–Peru agreement | Peru | Free |
| UK–Papua New Guinea agreement | Papua New Guinea | Free |
| UK–Palestinian Territories agreement | Palestinian Territories | Free |
| UK–Serbia agreement | Serbia | Free |
| UK–Solomon Islands agreement | Solomon Islands | Free |
| UK–Singapore agreement | Singapore | Free |
| UK–San Marino agreement | San Marino | Free |
| UK–Tunisia agreement | Tunisia | Free |
| UK–Türkiye agreement | Türkiye | Free |
| UK–Ukraine agreement | Ukraine | Free |
| UK–Vietnam agreement | Vietnam | Free |
| UK–Samoa agreement | Samoa | Free |
| UK–Kosovo agreement | Kosovo | Free |
| UK–South Africa agreement | South Africa | Free |
UK: imports by month
Main suppliers, last 12 months
| Country | Value | Share | Change |
|---|---|---|---|
| £2.1bn | 20.5% | +34.6% | |
| £1.8bn | 18.1% | -0.5% | |
| £922.8m | 9.2% | -9.4% | |
| £659.3m | 6.5% | -3.5% | |
| £568.4m | 5.6% | +0.6% | |
| £439.5m | 4.4% | -5.4% | |
| £391.4m | 3.9% | +1.8% | |
| £373.6m | 3.7% | -0.9% |
Same subheading in other tariffs
World trade in 2024
Trade value (US$) no reported trade < US$5mUS$5m+US$280m+US$2.8bn+> US$20.5bn
Exports: 206
- Germany: US$55.8bn
- Switzerland: US$42.2bn
- United States: US$31.4bn
- Ireland: US$28.3bn
- Italy: US$26.9bn
- Slovenia: US$23.3bn
- India: US$20.5bn
- Belgium: US$19.7bn
- France: US$18.9bn
- United Kingdom: US$14.7bn
- Spain: US$12.7bn
- Netherlands: US$11.9bn
- Singapore: US$9bn
- China: US$7.2bn
- Canada: US$7.1bn
- Sweden: US$6.8bn
- Hungary: US$6.6bn
- Denmark: US$6.2bn
- Japan: US$5.2bn
- Austria: US$4bn
- Poland: US$2.8bn
- Czechia: US$2.5bn
- Greece: US$2.5bn
- Israel: US$1.9bn
- Finland: US$1.9bn
- Mexico: US$1.8bn
- Romania: US$1.8bn
- Portugal: US$1.3bn
- Türkiye: US$1.2bn
- Bulgaria: US$955m
- Lithuania: US$749m
- South Korea: US$746m
- Australia: US$725m
- Croatia: US$697m
- Taiwan: US$607m
- Malta: US$585m
- Latvia: US$553m
- Slovakia: US$539m
- Brazil: US$530m
- Norway: US$527m
- Argentina: US$521m
- Hong Kong SAR China: US$502m
- Saudi Arabia: US$469m
- Cyprus: US$424m
- Thailand: US$387m
- Serbia: US$362m
- Guatemala: US$331m
- South Africa: US$307m
- Egypt: US$303m
- Indonesia: US$284m
- Jordan: US$280m
- Pakistan: US$268m
- Colombia: US$249m
- Russia: US$234m
- Malaysia: US$209m
- Vietnam: US$172m
- Ukraine: US$167m
- El Salvador: US$161m
- New Zealand: US$152m
- Kenya: US$149m
Trade value (US$) no reported trade < US$153mUS$153m+US$828m+US$3.3bn+> US$13.1bn
Imports: 224
- United States: US$75.6bn
- Switzerland: US$42.4bn
- Germany: US$25.8bn
- Belgium: US$20.1bn
- Italy: US$15.7bn
- China: US$14bn
- United Kingdom: US$13.1bn
- Japan: US$12.5bn
- France: US$12.2bn
- Spain: US$11.8bn
- Netherlands: US$11bn
- Slovenia: US$7.6bn
- Canada: US$7.6bn
- Russia: US$6.6bn
- Poland: US$5.6bn
- Ireland: US$4.7bn
- Australia: US$4.6bn
- Czechia: US$4.3bn
- Romania: US$4.2bn
- South Korea: US$3.9bn
- Austria: US$3.7bn
- Brazil: US$3.7bn
- Saudi Arabia: US$3.3bn
- Mexico: US$3.3bn
- Sweden: US$3.2bn
- Taiwan: US$2.9bn
- Denmark: US$2.8bn
- Hungary: US$2.5bn
- Portugal: US$2.3bn
- Greece: US$2.2bn
- United Arab Emirates: US$2.1bn
- Hong Kong SAR China: US$2bn
- Egypt: US$1.9bn
- Türkiye: US$1.9bn
- Colombia: US$1.7bn
- Vietnam: US$1.5bn
- Israel: US$1.5bn
- Slovakia: US$1.5bn
- Singapore: US$1.5bn
- Bulgaria: US$1.4bn
- South Africa: US$1.4bn
- Norway: US$1.4bn
- Ukraine: US$1.4bn
- Lithuania: US$1.3bn
- Finland: US$1.3bn
- Thailand: US$1.2bn
- Croatia: US$1.1bn
- Kuwait: US$1.1bn
- Serbia: US$1.1bn
- Philippines: US$1.1bn
- Kazakhstan: US$1.1bn
- Chile: US$1bn
- Uzbekistan: US$1bn
- Malaysia: US$1bn
- India: US$871m
- Argentina: US$828m
- Latvia: US$750m
- Iraq: US$739m
- New Zealand: US$688m
- Luxembourg: US$651m
Top exporters
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$55.8bn | 14.2% | |
| 2 | US$42.2bn | 10.8% | |
| 3 | US$31.4bn | 8% | |
| 4 | US$28.3bn | 7.2% | |
| 5 | US$26.9bn | 6.9% | |
| 6 | US$23.3bn | 5.9% | |
| 7 | US$20.5bn | 5.2% | |
| 8 | US$19.7bn | 5% | |
| 9 | US$18.9bn | 4.8% | |
| 10 | US$14.7bn | 3.8% |
Top importers
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$75.6bn | 19.3% | |
| 2 | US$42.4bn | 10.8% | |
| 3 | US$25.8bn | 6.6% | |
| 4 | US$20.1bn | 5.1% | |
| 5 | US$15.7bn | 4% | |
| 6 | US$14bn | 3.6% | |
| 7 | US$13.1bn | 3.3% | |
| 8 | US$12.5bn | 3.2% | |
| 9 | US$12.2bn | 3.1% | |
| 10 | US$11.8bn | 3% |
Import duty on this product around the world 165
The most-favoured-nation (MFN) duty each country applies to goods of this HS subheading: the average over its national tariff lines, with the lowest and highest line where they differ. Goods from countries with a trade agreement often pay less.
- 0%median duty
- 87number of duty-free countries (MFN)
- 17%highest: Iran, French Polynesia, Pakistan
165
| Importing country | MFN duty | lines from – to | data year |
|---|---|---|---|
| 2.5% | 2018 · HS 2012 | ||
| 0% | 2023 | ||
| 5% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 10% | 2021 · HS 2017 | ||
| 13% | 0% – 15% | 2021 · HS 2007 | |
| 10% | 0% – 14% | 2023 · HS 2017 | |
| 3.8% | 3% – 5% | 2023 | |
| 6% | 2021 · HS 2012 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2022 | ||
| 0% | 2023 | ||
| 8.8% | 0% – 25% | 2023 · HS 2017 | |
| 13% | 0% – 15% | 2022 · HS 2017 | |
| 3.8% | 3% – 5% | 2021 · HS 2017 | |
| 11% | 0% – 15% | 2023 | |
| 0% | 2023 | ||
| 13% | 0% – 25% | 2023 | |
| 0% | 2022 | ||
| 6.4% | 0% – 10% | 2023 · HS 2017 | |
| 5% | 0% – 10% | 2022 | |
| 0% | 2023 | ||
| 11% | 0% – 14% | 2023 · HS 2017 | |
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 12% | 2021 · HS 2002 | ||
| 5% | 2023 | ||
| 5% | 2023 | ||
| 6% | 2023 · HS 2017 | ||
| 0.5% | 0% – 4% | 2023 | |
| 7.9% | 5% – 10% | 2023 · HS 2017 | |
| 0% | 2021 · HS 2017 | ||
| 5% | 2023 | ||
| 0% | 2022 · HS 2017 | ||
| 2.1% | 0% – 5% | 2023 | |
| 0% | 2023 · HS 2017 | ||
| 1% | 2023 · HS 2017 | ||
| 0% | 2023 · HS 2017 | ||
| 0.6% | 0% – 3% | 2023 | |
| 5.7% | 5% – 10% | 2023 · HS 2017 | |
| 3.3% | 0% – 5% | 2019 · HS 2017 | |
| 5% | 2022 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 5% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 15% | 2023 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2022 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 8.8% | 0% – 10% | 2023 · HS 2012 | |
| 10% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 13% | 0% – 15% | 2023 · HS 2017 | |
| 0% | 2020 · HS 2017 | ||
| 2.5% | 0% – 5% | 2023 | |
| 0% | 2023 | ||
| 0% | 2023 | ||
| 10% | 2023 | ||
| 4.5% | 0% – 5% | 2023 | |
| 17% | 5% – 32% | 2020 · HS 2017 | |
| 0% | 2022 · HS 2017 | ||
| 8.8% | 0% – 15% | 2023 | |
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2002 | ||
| 0% | 2023 | ||
| 3.8% | 3% – 5% | 2021 · HS 2017 | |
| 10% | 2023 · HS 2017 | ||
| 5% | 2020 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 1.5% | 0% – 15% | 2023 · HS 2017 | |
| 4% | 2021 · HS 2017 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 | ||
| 13% | 0% – 15% | 2023 · HS 2017 | |
| 14% | 2.5% – 40% | 2023 | |
| 0% | 2023 | ||
| 1.5% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2021 · HS 2017 | ||
| 11% | 10% – 15% | 2023 | |
| 0% | 2023 | ||
| 2.5% | 0% – 5% | 2023 | |
| 0% | 2023 | ||
| 0% | 2023 | ||
| 5% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 14% | 11% – 20% | 2023 | |
| 0% | 2023 · HS 2012 | ||
| 0% | 2017 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 10% | 0% – 14% | 2023 · HS 2017 | |
| 6% | 2023 · HS 2017 | ||
| 4.2% | 0% – 5% | 2023 | |
| 0% | 2023 | ||
| 3.8% | 3% – 5% | 2021 · HS 2017 | |
| 0% | 2023 | ||
| 0% | 2020 · HS 2017 | ||
| 5% | 2019 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 5% | 2023 · HS 2017 | ||
| 5% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 8% | 2023 | ||
| 3.8% | 0% – 15% | 2023 | |
| 7.5% | 0% – 10% | 2023 | |
| 8.8% | 0% – 10% | 2023 · HS 2012 | |
| 2.5% | 0% – 5% | 2021 · HS 2017 | |
| 9.2% | 0% – 10% | 2023 | |
| 0% | 2021 · HS 2017 | ||
| 13% | 0% – 15% | 2023 · HS 2007 | |
| 0% | 2023 | ||
| 5% | 2020 · HS 2012 | ||
| 5% | 2021 · HS 2012 | ||
| 0% | 2023 | ||
| 7.9% | 0% – 10% | 2023 | |
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 8.5% | 0% – 12% | 2023 · HS 2012 | |
| 0% | 2023 | ||
| 0% | 2017 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 · HS 2017 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 0% | 2023 | ||
| 10% | 0% – 14% | 2023 · HS 2017 | |
| 0% | 2021 · HS 2017 | ||
| 0% | 2023 | ||
| 10% | 0% – 14% | 2023 · HS 2017 | |
| 2.5% | 0% – 5% | 2023 | |
| 4% | 2021 · HS 2012 | ||
| 2.5% | 0% – 5% | 2017 · HS 2017 | |
| 0% | 2023 | ||
| 0.1% | 0% – 0.1% | 2023 |
Tariff data years 2017–2023; rates may have changed since. · UNCTAD TRAINS, accessed via WITS (World Bank)
Classifications and correspondences
Where this HS subheading sits in the United Nations' statistical classifications, and which codes it had in earlier editions of the Harmonized System.
- SITC Rev. 4
- 54293 Medicaments, n.e.s., put up in measured doses/in forms/packings for retail sale
- End use (BEC Rev. 5)
- Intermediate goods · BEC 711220
- CPC 2.1 product
- 35260 Medicaments, for therapeutic or prophylactic uses
- ISIC Rev. 4 activity
- 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products
Earlier HS editions
| HS | Code | |
|---|---|---|
| 2017 | 3004.90 | changed |
| 2012 | 3004.90 | changed |
| 2007 | 3004.90 | changed |
| 2002 | 3004.90 | changed |
| 1996 | 3004.90 | changed |
| 1992 | 3004.90 | changed |
Correspondence tables of the United Nations Statistics Division (UNSD)
Binding rulings for similar goods 562
Decisions of U.S. Customs and Border Protection (CROSS) and HMRC (Advance Tariff Rulings) on goods classified here. A ruling binds only its holder, but shows how the authorities classify similar goods. The descriptions are the authorities’ own, in English.
- N364941 U.S. CBP
The tariff classification of Linezolid Tablets in dosage form, from India
- N364942 U.S. CBP
The tariff classification of Diltiazem Hydrochloride Extended-Release Capsules in dosage form, from India
- N364416 U.S. CBP
The tariff classification of Ranolazine Extended-Release Tablets in dosage form, from India
- N364415 U.S. CBP
The tariff classification of Bupropion Hydrochloride Extended-Release Tablets in dosage form, from India
- N363611 U.S. CBP
The tariff classification of Potassium Chloride Extended-Release (ER) Tablets in dosage form, from the United Kingdom
- N363288 U.S. CBP
The tariff classification of Tegoprazan Tablets in dosage form, from South Korea
- 600015874 HMRC
A sterile physiological saline solution Used as an extraocular and intraocular irrigation solution in eye surgery Presented in a plastic bottle with a capacity of 15 ml, and in glass bottles or flexible plastic bags with a capacity of 250 or 500 ml
- 600016281 HMRC
A sterile inhalation saline solution intended to mobilise secretions in the respiratory tract caused by respiratory diseases. The solution contains 3% sodium chloride and is free from preservatives. It is packaged in 20 × 4 ml ampoules for use with a jet, membrane, or ultrasonic nebuliser.
- 600015890 HMRC
Formoline L112 tablets to support weight management and reduction of dietary fat absorption and lowering of LDL cholesterol active component is polyglucosamine, also contain excipients used in tablet manufacture, including binders, fillers and coating materials packed in boxes of 64 tablets, with…
- 600013517 HMRC
radiopharmaceutical containing the radioactive isotope Lutetium-177 single patient dose, administered intravenously, via the vial Physical form: liquid Use: in clinical trials for assessment of its performance as a therapeutic medicine in humans Packaging :a vial held within shielded container to…
- 600013518 HMRC
Radiopharmaceutical containing the radioactive isotope Actinium-225. single patient dose, administered intravenously, via the vial Physical form: a liquid Used in clinical trials for assessment of its performance as a therapeutic medicine in humans Packaging: single use vial
- 600012665 HMRC
Submucosal Lifting Agent used in endoscopic procedures to create a cushion-like space between the mucosa and underlining tissue Single use
562 rulings in total for this code
Recent rule changes mentioning this code
Acts whose text cites this code or its heading. Check the act itself: a code can be cited for reasons other than a change of its duty.
-
FR Doc. 2026-19498 · 91 FR 60360 · Source: federalregister.gov
-
FR Doc. 2026-14542 · 91 FR 45516 · Source: federalregister.gov
-
Harmonized Tariff Schedule of the United States — 2026 HTS Revision 11
2026HTSRev11 · Source: hts.usitc.gov
-
FR Doc. 2026-11158 · 91 FR 33854 · Source: federalregister.gov
-
Recommended Modifications in the Harmonized Tariff Schedule
FR Doc. 2026-07753 · 91 FR 21311 · Source: federalregister.gov
-
Harmonized Tariff Schedule of the United States — 2026 HTS Revision 2
2026HTSRev2 · Source: hts.usitc.gov
The UK Global Tariff has one tariff line for subheading 3004.90; the duty is duty-free.
Subheading 3004.90 is a single line in the EU Combined Nomenclature, where the duty is duty-free.
156 countries pay no duty in the UK thanks to trade agreements and preference schemes such as DCTS Comprehensive and European Union, against a standard rate of Free.
In the UK, additional duty of 35% applies on top of the customs duty to goods from Belarus and Russia.
Imports of other medicines, dosed or for retail sale into the UK came to £10.1bn between September 2025 and August 2026 (up 7% on the year before); Germany supplied 21%, followed by United States.
In 2024, countries exported other medicines, dosed or for retail sale worth US$391.5bn (+3.2% year on year).
The largest exporter was Germany (US$55.8bn), followed by Switzerland.
Products classified here
Questions and answers
What is the HS code for medicaments: other?
Medicaments: other fall under HS subheading 3004.90, part of heading 3004, in section VI of the Harmonized System.
What is the import duty on medicaments: other in the UK?
Under the UK Global Tariff, imports under 3004.90 from countries without a preferential agreement are free of duty. Preferential rates, anti-dumping duties and VAT are not included.
What is the import duty on medicaments: other in the EU?
Under the EU Combined Nomenclature, imports under 3004.90 from countries without a preferential agreement are free of duty. Preferential rates, anti-dumping duties and VAT are not included.
Which country exports the most medicaments: other?
Germany, with US$55.8bn in 2024 (14.2% of world exports).
Which countries can export other medicines, dosed or for retail sale to the UK duty-free?
156 countries pay no duty under a trade agreement or preference scheme, among them partners under DCTS Comprehensive, European Union, CARIFORUM. The goods must meet the agreement’s rules of origin and the importer needs proof of origin; otherwise the standard rate of Free applies. Pick a country above to see its rate.
Is there anti-dumping duty on other medicines, dosed or for retail sale?
The UK charges additional duty of 35% on goods from Belarus and Russia. Lower rates apply to the named exporters listed in the measure.
Where does the UK import other medicines, dosed or for retail sale from?
In the 12 months to August 2026, the largest suppliers were Germany (21%), United States (18%) and Ireland (9%), out of total imports of £10.1bn.
Typical products
Everyday names, not part of the legal text.